支氣管動脈灌注化療與全身靜脈化療治療晚期非小細(xì)胞肺癌的療效及安全性的Meta分析
[Abstract]:Background & objective: lung cancer is one of the malignant tumors with the highest morbidity and mortality in China. The purpose of this study was to investigate the efficacy and safety of pulse infusion chemotherapy and intravenous systemic chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: the online knowledge service platform of PubMed, Cochranelibrary, (CBM), China knowledge Resource General Database (CNKI),) was searched by computer. To collect the Chinese and English literature on clinical controlled trials of bronchial artery infusion chemotherapy and systemic intravenous chemotherapy published at home and abroad from 2000 to 2014, and to screen the literature strictly according to the inclusion criteria and evaluate the quality of the literature. The final selected documents were analyzed by Meta using RevMan5.0 software. Results: a total of 11 meta-analysis papers showed that the effective rate of bronchial infusion chemotherapy group was significantly higher than that of systemic intravenous chemotherapy group (RRN 1.57; 95CII 1.37-1.82; P0.001; 120.0%), but there was no significant difference in 1-year survival rate between the two groups (RRN 1.10; 95 CI 0.91-1.33P0.30I224%). The incidence of thrombocytopenia in bronchial artery infusion chemotherapy group was significantly lower than that in systemic intravenous chemotherapy group (RRR 0.64; 95 CI 0.30-1.37; P0. 006; 120%), but there was no significant difference in the incidence of leukopenia between the two groups (RRR0. 77; 95CI0. 56-1. 04; P0. 09; 1287%), and there was no significant difference in the incidence of nausea and vomiting (RR0. 64; 95CIT 0. 30-1.37; P0. 25; I298%). Conclusion: the effective rate of bronchial arterial chemotherapy on advanced non-small cell lung cancer is significantly higher than that of systemic intravenous chemotherapy, and to some extent can reduce the occurrence of some adverse reactions. It can be used as one of the first treatment methods in patients with advanced non-small cell lung cancer (NSCLC).
【學(xué)位授予單位】:重慶醫(yī)科大學(xué)
【學(xué)位級別】:碩士
【學(xué)位授予年份】:2015
【分類號】:R734.2
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 王季穎;蔡勇;;支氣管動脈灌注化療聯(lián)合全身靜脈化療在中央型非小細(xì)胞肺癌中的應(yīng)用[J];中國醫(yī)藥指南;2010年04期
2 陸云飛;曾健;廖清華;林堅;黃源;陳俊強;田磊;解乃昌;;胃癌根治術(shù)后動脈區(qū)域灌注化療與全身靜脈化療的臨床療效比較[J];中華胃腸外科雜志;2006年04期
3 李方;焦順昌;楊俊蘭;戴廣海;趙宏;李瑛;;侵犯漿膜層合并淋巴結(jié)轉(zhuǎn)移胃癌術(shù)后輔助腹腔聯(lián)合全身靜脈化療的生存分析[J];軍醫(yī)進(jìn)修學(xué)院學(xué)報;2009年04期
4 鄒慶偉;蒲艷;蒲敏;;腹腔熱灌注聯(lián)合全身靜脈化療在胃癌術(shù)后應(yīng)用的效果觀察[J];中國醫(yī)療前沿;2013年05期
5 于斌,潘德強,馮起校,何雙蘭,袁國奇,李清水;CT引導(dǎo)下介入法治療無手術(shù)指征肺癌的臨床探討[J];國際醫(yī)藥衛(wèi)生導(dǎo)報;2002年10期
6 馮起校;何雙蘭;袁國奇;李清水;;CT引導(dǎo)下介入法治療無手術(shù)指征肺癌的臨床探討[J];海南醫(yī)學(xué);2006年03期
7 韓光宏;蔣林哲;王愛光;;術(shù)中及術(shù)后早期腹腔熱灌注化療聯(lián)合全身靜脈化療治療進(jìn)展期胃癌[J];中國臨床研究;2011年07期
8 苑靜波,史金英,啜振華;中晚期肺癌的介入治療與全身靜脈化療療效觀察[J];實用腫瘤雜志;2005年04期
9 李忠福;蘇東峰;張延軍;王勇強;段鳳霞;;支氣管動脈灌注化療與全身靜脈化療治療中晚期肺癌療效觀察[J];當(dāng)代醫(yī)學(xué)(中國介入放射學(xué));2008年04期
10 艾寧;冀宏;李智崗;李順宗;趙俊京;;結(jié)直腸癌肝轉(zhuǎn)移動脈化療栓塞與全身靜脈化療的療效對比分析[J];臨床放射學(xué)雜志;2010年09期
相關(guān)會議論文 前1條
1 楊升;馮睿;潘璋弛;江濤;徐倩;陳強;;胃癌根治術(shù)后全身靜脈化療聯(lián)合腹腔灌注化療與單純靜脈化療療效比較的系統(tǒng)性回顧及薈萃分析[A];中國腫瘤內(nèi)科進(jìn)展 中國腫瘤醫(yī)師教育(2014)[C];2014年
相關(guān)碩士學(xué)位論文 前2條
1 魏家瑋;支氣管動脈灌注化療與全身靜脈化療治療晚期非小細(xì)胞肺癌的療效及安全性的Meta分析[D];重慶醫(yī)科大學(xué);2015年
2 張瑞珍;支氣管動脈灌注化療聯(lián)合全身靜脈化療治療中晚期肺癌的療效觀察[D];重慶醫(yī)科大學(xué);2010年
,本文編號:2144433
本文鏈接:http://sikaile.net/yixuelunwen/zlx/2144433.html